At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
rituximab +2 moredrug
Likely dose
rituximab 375 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Anti-tumor Activity and Safety of a Combination of Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma.
In Brief
A Phase 2 clinical trial evaluating rituximab, fludarabine, and 1 other intervention for Follicular Lymphoma. Completed, enrolled 50 participants across 16 sites.
Detailed Summary
This study is a multicentric trial evaluating the efficacy of the RFM regimen in patients aged 18 to 75 years with relapsed/refractory follicular non-Hodgkin's lymphoma (NHL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFollicular Lymphoma
CountriesFrance
Collaborators--
Timeline
Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2001
First PostedSep 2005
Primary CompletionDec 2006
TodayJul 2026
First PostedSep 15, 2005
Enrollment StartApr 1, 2001
Primary CompletionDec 1, 2006
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 20.8 years ago
Interventions
rituximabdrug
375 mg/m² IV, D1 each cycle during 4 cycles
fludarabinedrug
40 mg/m²/day IV , D1 each cycle during 4 cycles
mitoxantronedrug
10 mg/m² IV, D2-3-4 each cycle during 4 cycles